Working… Menu

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01616199
Recruitment Status : Terminated (slow accrual)
First Posted : June 11, 2012
Last Update Posted : May 16, 2018
Information provided by (Responsible Party):
Seattle Genetics, Inc. ( Cascadian Therapeutics Inc. )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 2014
Actual Study Completion Date : March 2015
Certification/Extension First Submitted : April 30, 2015